<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17677" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Antibiotics</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wermuth</surname>
            <given-names>Harrison R.</given-names>
          </name>
          <aff>Michigan State University College of Human Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Calhoun</surname>
            <given-names>Chara</given-names>
          </name>
          <aff>Medical University of South Carolina</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hall</surname>
            <given-names>Gregory A.</given-names>
          </name>
          <aff>MUSC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Harrison Wermuth declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Chara Calhoun declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gregory Hall declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17677.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Antibiotics are common agents used in modern healthcare. This was not always the case. From ancient times, people sought ways to treat those afflicted with infections. Dyes, molds, and even heavy metals were thought to hold promise for healing. Various microorganisms have medical significance, including bacteria, viruses, fungi, and parasites. Antibiotics are compounds that target bacteria and, thus, are intended to treat and prevent bacterial infections. This activity will examine the various classes of antibiotics, their mechanisms of action, bacterial susceptibilities, and potential adverse events.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the various classes of antibiotic medications.</p></list-item><list-item><p>Explain the various mechanisms of action of different classes of antibiotics.</p></list-item><list-item><p>Review the potential adverse effects both of antibiotics in general and class-specific side effects.</p></list-item><list-item><p>Summarize the monitoring requirements for patients receiving antibiotic therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17677&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17677">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17677.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Antibiotics are common agents used in modern healthcare. This was not always the case. From ancient times, people sought ways to treat those with infections. Dyes, molds, and even heavy metals were thought to hold promise for healing.<xref ref-type="bibr" rid="article-17677.r1">[1]</xref>&#x000a0;Various microorganisms have medical significance, including bacteria, viruses, fungi, and parasites. Antibiotics are compounds that target bacteria and, thus, are intended to treat and prevent bacterial infections.</p>
      </sec>
      <sec id="article-17677.s3" sec-type="Function">
        <title>Function</title>
        <p>
<bold>Classification</bold>
</p>
        <p>The pharmacology behind antibiotics includes destroying the bacterial cell by either preventing cell reproduction or changing a necessary cellular function or process within the cell. Antimicrobial agents are classically grouped into two main categories based on their in vitro effect on bacteria: bactericidal and bacteriostatic. Common teaching often explains that bactericidal antibiotics "kill" bacteria and bacteriostatic antibiotics "prevent the growth" of bacteria. The true definition is not so simple. To accurately define each category, the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) must be understood. The lowest concentration that inhibits visible bacterial growth at 24 hours is the MIC.<xref ref-type="bibr" rid="article-17677.r2">[2]</xref>&#x000a0;The MBC is the concentration of an antibiotic that reduces bacterial density by 1000-fold at 24 hours.<xref ref-type="bibr" rid="article-17677.r2">[2]</xref>&#x000a0;</p>
        <p>Bacteriostatic activity is further defined by an MBC to MIC ratio greater than 4, whereas an MBC to MIC ratio less than or equal to 4 is bactericidal.<xref ref-type="bibr" rid="article-17677.r2">[2]</xref>&#x000a0;The clinical implications of antibiotic efficacy depend heavily on many factors not limited to: pharmacokinetic and pharmacodynamic principles, the particular bacteria, bacterial load, and site of infection. This is further complicated by the ability of some bacteriostatic antibiotics to exhibit bactericidal activity against particular bacteria.<xref ref-type="bibr" rid="article-17677.r3">[3]</xref>&#x000a0;Therefore, bacteriostatic antibiotics also kill bacteria, but the laboratory definition makes it seem as if they do not. For example, a bacteriostatic antibiotic such as linezolid can be bactericidal against <italic toggle="yes">Streptococcus pneumoniae</italic>.<xref ref-type="bibr" rid="article-17677.r3">[3]</xref>&#x000a0;This concept works in reverse, and bactericidal antimicrobials may also be bacteriostatic against certain bacterial strains and conditions. Conflicting data exist as to&#x000a0;whether the necessity for bactericidal antibiotics is needed for severely ill or immunosuppressed patients.<xref ref-type="bibr" rid="article-17677.r3">[3]</xref></p>
        <p><bold>Types of Antimicrobial Agents</bold><xref ref-type="bibr" rid="article-17677.r3">[3]</xref>&#x000a0;&#x000a0;</p>
        <p>
<bold>Drug Class and Specific Antibiotics</bold>
</p>
        <p>
<bold>Bacteriostatic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Glycylcyclines: Tigecycline</p>
          </list-item>
          <list-item>
            <p>Tetracyclines: Doxycycline, minocycline</p>
          </list-item>
          <list-item>
            <p>Lincosamides: Clindamycin</p>
          </list-item>
          <list-item>
            <p>Macrolides: Azithromycin, clarithromycin, erythromycin</p>
          </list-item>
          <list-item>
            <p>Oxazolidinones: Linezolid</p>
          </list-item>
          <list-item>
            <p>Sulfonamides: Sulfamethoxazole</p>
          </list-item>
        </list>
        <p>
<bold>Bactericidal</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Aminoglycosides: Tobramycin, gentamicin, amikacin</p>
          </list-item>
          <list-item>
            <p>Beta-lactams (penicillins, cephalosporins, carbapenems): Amoxicillin, cefazolin, meropenem</p>
          </list-item>
          <list-item>
            <p>Fluoroquinolones: Ciprofloxacin, levofloxacin, moxifloxacin</p>
          </list-item>
          <list-item>
            <p>Glycopeptides: Vancomycin</p>
          </list-item>
          <list-item>
            <p>Cyclic Lipopeptides: Daptomycin</p>
          </list-item>
          <list-item>
            <p>Nitroimidazoles: Metronidazole</p>
          </list-item>
        </list>
        <p>
<bold>Pharmacokinetics and Pharmacodynamics</bold>
</p>
        <p>Pharmacokinetic (PK) and pharmacodynamic (PD) parameters are used together to maximize the efficacy of antimicrobial therapy through optimization of dosing in patients. Absorption, distribution, metabolism, and excretion are the PK components that affect the antibiotic concentration&#x000a0;over time.<xref ref-type="bibr" rid="article-17677.r4">[4]</xref>&#x000a0;These processes describe how an antibiotic moves through the body from the time it enters the body until&#x000a0;the parent drug or metabolites&#x000a0;are removed. PD of an antibiotic describes the drug effect within the body when it reaches the infection target. The main principles that guide PD are the percent of the time the free drug is over the MIC, the amount of free drug area under the concentration to MIC, and the maximum concentration to MIC.<xref ref-type="bibr" rid="article-17677.r5">[5]</xref>&#x000a0;</p>
        <p>Bactericidal activity is either&#x000a0;concentration-dependent or time-dependent. If an antibiotic displays concentration-dependent killing, for example, fluoroquinolones or daptomycin, the efficacy of bacterial killing increases as the concentration of the antibiotic increases.<xref ref-type="bibr" rid="article-17677.r6">[6]</xref>&#x000a0;Penicillins and tetracyclines are time-dependent; therefore, the duration of the effective concentration of these antibiotics determines bactericidal activity.<xref ref-type="bibr" rid="article-17677.r6">[6]</xref></p>
        <p>After an antibiotic is absorbed, the distribution influences the extent of antimicrobial activity. The total amount of drug in the body to serum concentration is the volume of distribution.<xref ref-type="bibr" rid="article-17677.r5">[5]</xref>&#x000a0;The level of protein binding will affect the availability of the active drug at the site of infection. If an antibiotic is highly protein-bound, there will be less free drug available for an antimicrobial effect, as seen in patients with hypoalbuminemia.<xref ref-type="bibr" rid="article-17677.r5">[5]</xref>&#x000a0;Increased adipose tissue in a patient will increase the volume of distribution if a drug has high lipophilicity properties.<xref ref-type="bibr" rid="article-17677.r7">[7]</xref></p>
        <p>The location of infection is crucial to note because some antibiotics are inappropriate for treating certain infections. In the treatment of meningitis, for example, the penetration of the blood-brain barrier is critical if one wants to achieve therapeutic antibiotic levels at the site of infection to prevent treatment failure.<xref ref-type="bibr" rid="article-17677.r5">[5]</xref></p>
      </sec>
      <sec id="article-17677.s4" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>
<bold>Complications</bold>
</p>
        <p>
<bold>Adverse Reactions</bold>
</p>
        <p>All medications have the potential for an adverse reaction, and antibiotics are no exception. One in&#x000a0;five hospitalized patients has&#x000a0;been shown to develop an adverse reaction to an antibiotic,&#x000a0;and&#x000a0;nearly the same proportion of drug-related Emergency Department visits are due to adverse antibiotic reactions.<xref ref-type="bibr" rid="article-17677.r8">[8]</xref><xref ref-type="bibr" rid="article-17677.r9">[9]</xref>&#x000a0;An immune-mediated reaction or hypersensitivity is classified as an allergy.<xref ref-type="bibr" rid="article-17677.r10">[10]</xref>&#x000a0;This includes IgE-mediated anaphylaxis and angioedema. Medications often reach harmful levels in the body due to reduced metabolism and elimination, or high dosing regimens can cause toxicity due to supratherapeutic drug levels.<xref ref-type="bibr" rid="article-17677.r11">[11]</xref>&#x000a0;If a reaction occurs that is not mediated by the immune system and is unrelated to the drug level; then it is considered a side effect.<xref ref-type="bibr" rid="article-17677.r11">[11]</xref></p>
        <p>The anticipation&#x000a0;of adverse events is warranted when initiating antimicrobial therapy. Certain patients are at higher risk, for example, the elderly, patients with multiple co-morbidities, and hospitalized patients.<xref ref-type="bibr" rid="article-17677.r8">[8]</xref>&#x000a0;It is important to monitor patients for reactions as many develop&#x000a0;over time. Some antibiotics necessitate monitoring drug levels to guide therapy for efficacy and prevention of adverse effects such as vancomycin and aminoglycosides.<xref ref-type="bibr" rid="article-17677.r12">[12]</xref>&#x000a0;Renal toxicities may develop if these antimicrobials maintain high trough levels; therefore, monitoring renal function is necessary and measuring drug levels.</p>
        <p>
<bold>Adverse Reactions Associated with Organ Systems</bold>
</p>
        <p>
<bold>Renal</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute tubular necrosis</p>
          </list-item>
          <list-item>
            <p>Interstitial nephritis</p>
          </list-item>
          <list-item>
            <p>Renal failure</p>
          </list-item>
          <list-item>
            <p>Crystallization in renal tubules<xref ref-type="bibr" rid="article-17677.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Cardiac</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>QT prolongation<xref ref-type="bibr" rid="article-17677.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Hematologic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Thrombocytopenia</p>
          </list-item>
          <list-item>
            <p>Leukopenia</p>
          </list-item>
          <list-item>
            <p>Agranulocytosis</p>
          </list-item>
          <list-item>
            <p>Abnormal platelet aggregation</p>
          </list-item>
          <list-item>
            <p>INR increase (often due to drug interactions)<xref ref-type="bibr" rid="article-17677.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Dermatologic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Rash</p>
          </list-item>
          <list-item>
            <p>Erythema multiforme</p>
          </list-item>
          <list-item>
            <p>Stevens-Johnson syndrome</p>
          </list-item>
          <list-item>
            <p>Toxic epidermal necrolysis<xref ref-type="bibr" rid="article-17677.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Neurologic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ototoxicity</p>
          </list-item>
          <list-item>
            <p>Vestibular dysfunction</p>
          </list-item>
          <list-item>
            <p>Seizure</p>
          </list-item>
          <list-item>
            <p>Peripheral neuropathy<xref ref-type="bibr" rid="article-17677.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Other</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hepatotoxicity</p>
          </list-item>
          <list-item>
            <p>Myopathy</p>
          </list-item>
          <list-item>
            <p>Electrolyte abnormalities (i.e., hypokalemia, hypoglycemia)</p>
          </list-item>
          <list-item>
            <p>Drug-induced fever</p>
          </list-item>
          <list-item>
            <p>Drug-induced diarrhea<xref ref-type="bibr" rid="article-17677.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Antibiotic Resistance</bold>
</p>
        <p>The increased use of antimicrobial agents in clinical practice and other industries such as livestock farming has led to bacterial resistance to antibiotic agents. Bacteria have developed mechanisms to promote this resistance to survive.&#x000a0;&#x000a0;</p>
        <p>The MIC of a bacterial isolate can serve as a metric for bacterial susceptibility to certain antibiotics.<xref ref-type="bibr" rid="article-17677.r13">[13]</xref>&#x000a0;A high MIC above the susceptibility threshold to an antibiotic will report as a resistant infection. Bacteria may possess resistance to an antimicrobial agent due to intrinsic or acquired properties. Not all antibiotics are effective against all types of bacteria. If a bacterium does not contain the target for a particular antibiotic, it is known to have intrinsic resistance.<xref ref-type="bibr" rid="article-17677.r14">[14]</xref>&#x000a0;Vancomycin, an antibiotic known to target work against gram-positive bacteria, cannot cross the cell wall of gram-negative bacteria.<xref ref-type="bibr" rid="article-17677.r15">[15]</xref>&#x000a0;Also, beta-lactam antibiotics require a cell wall to function and, therefore, will not be effective against bacteria such as <italic toggle="yes">Mycoplasma </italic>species that lack this cellular component.</p>
        <p>Bacteria also have the capability to gain resistance through attaining resistance genes from other bacteria or developing a mutation resulting in reduced or elimination of antibiotic efficacy. This type of resistance is known as acquired resistance.<xref ref-type="bibr" rid="article-17677.r14">[14]</xref></p>
        <p>More than one type of bacterial resistance may be present in a bacterial organism. Common resistance strategies are listed&#x000a0;here.</p>
        <p>
<bold>Mechanisms of Resistance and Examples</bold>
</p>
        <p>
<bold>Reducing Intracellular Antibiotic Concentrations</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Increased efflux</p>
          </list-item>
          <list-item>
            <p>Decreased influx<xref ref-type="bibr" rid="article-17677.r14">[14]</xref><xref ref-type="bibr" rid="article-17677.r15">[15]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Antibiotic Inactivation</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Enzymatic modification</p>
          </list-item>
          <list-item>
            <p>Chemical degradation<xref ref-type="bibr" rid="article-17677.r14">[14]</xref><xref ref-type="bibr" rid="article-17677.r15">[15]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Target Site Alteration</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Mutation of the target site</p>
          </list-item>
          <list-item>
            <p>Antibiotic modification</p>
          </list-item>
          <list-item>
            <p>Target site protection</p>
          </list-item>
          <list-item>
            <p>Elimination of the target site<xref ref-type="bibr" rid="article-17677.r14">[14]</xref><xref ref-type="bibr" rid="article-17677.r15">[15]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17677.s5" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>
<bold>Approach to Antimicrobial Therapy</bold>
</p>
        <p>The causative organisms and infection source are not always&#x000a0;known when a patient first presents.&#x000a0;Antibiotic therapy is often initiated before an exact infectious disease diagnosis, and microbiological results are available. Antibiotics used in this manner are referred to as empiric therapy. This approach attempts to cover all potential pathogens. When microbiology tests result and antibiotic susceptibilities are known, definitive antibiotic treatment can be tailored to the specific infection etiology.<xref ref-type="bibr" rid="article-17677.r16">[16]</xref></p>
        <p>Prophylactic therapy is used to prevent infections in patients who do not have an active infection. Immunocompromised patients may receive prophylaxis against specific opportunistic pathogens. Prophylactic antibiotics are also used before surgical procedures and traumatic injuries such as open fractures and animal bites.<xref ref-type="bibr" rid="article-17677.r16">[16]</xref></p>
        <p>The severity of potential bacterial infection will determine the level of aggressiveness in antibiotic therapy. For example, in a life-threatening infectious disease such as sepsis, empiric broad-spectrum parenteral antibiotics should be administered quickly after sepsis identification and continued until more information is gathered regarding the etiology and causative bacteria.<xref ref-type="bibr" rid="article-17677.r12">[12]</xref>&#x000a0;Empiric antibiotics are used to cover all potential bacteria before culture results. After bacterial cultures are available and have resulted, antibiotics can be deescalated to only what is necessary. This approach is termed directed antibiotic therapy.<xref ref-type="bibr" rid="article-17677.r16">[16]</xref>&#x000a0;Often, empiric antibiotics are broad-spectrum, which refers to medications targeting many different bacterial classes (i.e., gram-positive, gram-negative, and anaerobic bacteria). In a simple skin and soft tissue infection that does not require hospitalization, narrower spectrum antibiotics may&#x000a0;be given orally.<xref ref-type="bibr" rid="article-17677.r12">[12]</xref></p>
        <p>In addition to the possible source(s) of infection, likely pathogens, and situation urgency, different patient factors&#x000a0;merit&#x000a0;consideration.<xref ref-type="bibr" rid="article-17677.r12">[12]</xref>&#x000a0;Patient age, medication allergies, renal and hepatic function, past medical history, the presence&#x000a0;of an immunocompromised state, and recent antibiotic usage need to be&#x000a0;evaluated before an antibiotic selection. Many of these patient factors contribute to the pharmacodynamics and pharmacokinetics of antibiotics that will influence dosing to optimize efficacy.</p>
      </sec>
      <sec id="article-17677.s6" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>
<bold>A Word on Antimicrobial Stewardship</bold>
</p>
        <p>In the United States, it has been reported that nearly half of the antibiotics prescribed were incorrect in some way, and almost one-third of antibiotics were deemed unnecessary in hospitalized patients.<xref ref-type="bibr" rid="article-17677.r17">[17]</xref>&#x000a0;Appropriate antibiotic use has become a public health issue (CDC 19). The practice of antimicrobial stewardship revolves around the concept of optimizing antimicrobial therapy and reducing adverse events through economically responsible methods.<xref ref-type="bibr" rid="article-17677.r18">[18]</xref>&#x000a0;These interprofessional programs work to identify ways to improve patient outcomes. Stewardship programs are increasingly becoming more common to address issues related to antibiotic usage, including combating antimicrobial resistance.</p>
        <p>Antibiotic therapy and accompanying stewardship require the effort of an interprofessional healthcare team that includes physicians (MDs and DOs), mid-level practitioners (NPs and PAs), pharmacists, and nursing staff. This includes only using these agents when clinically indicated, targeted therapy based on the susceptibility of the infectious organism, and monitoring of side effects and, where indicated,&#x000a0;drug levels. Employing interprofessional strategies with open information sharing can improve therapeutic results with antibiotic therapy and minimize adverse events. [Level 5]</p>
      </sec>
      <sec id="article-17677.s7">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17677&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17677">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17677/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17677">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17677.s8">
        <title>References</title>
        <ref id="article-17677.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gould</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Antibiotics: from prehistory to the present day.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>572</fpage>
            <page-range>572-5</page-range>
            <pub-id pub-id-type="pmid">26851273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17677.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pankey</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Sabath</surname>
                <given-names>LD</given-names>
              </name>
            </person-group>
            <article-title>Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections.</article-title>
            <source>Clin Infect Dis</source>
            <year>2004</year>
            <month>Mar</month>
            <day>15</day>
            <volume>38</volume>
            <issue>6</issue>
            <fpage>864</fpage>
            <page-range>864-70</page-range>
            <pub-id pub-id-type="pmid">14999632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17677.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nemeth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oesch</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kuster</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>70</volume>
            <issue>2</issue>
            <fpage>382</fpage>
            <page-range>382-95</page-range>
            <pub-id pub-id-type="pmid">25266070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17677.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sy</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Zhuang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Derendorf</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2016</year>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>93</fpage>
            <page-range>93-114</page-range>
            <pub-id pub-id-type="pmid">26652832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17677.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Onufrak</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Forrest</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.</article-title>
            <source>Clin Ther</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>38</volume>
            <issue>9</issue>
            <fpage>1930</fpage>
            <page-range>1930-47</page-range>
            <pub-id pub-id-type="pmid">27449411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17677.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ambrose</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Bhavnani</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Rubino</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Louie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gumbo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Forrest</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drusano</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.</article-title>
            <source>Clin Infect Dis</source>
            <year>2007</year>
            <month>Jan</month>
            <day>01</day>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>79</fpage>
            <page-range>79-86</page-range>
            <pub-id pub-id-type="pmid">17143821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17677.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mui</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Holubar</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Deresinski</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Comprehensive Guidance for Antibiotic Dosing in Obese Adults.</article-title>
            <source>Pharmacotherapy</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>37</volume>
            <issue>11</issue>
            <fpage>1415</fpage>
            <page-range>1415-1431</page-range>
            <pub-id pub-id-type="pmid">28869666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17677.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tamma</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Avdic</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>DX</given-names>
              </name>
              <name>
                <surname>Dzintars</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cosgrove</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Association of Adverse Events With Antibiotic Use in Hospitalized Patients.</article-title>
            <source>JAMA Intern Med</source>
            <year>2017</year>
            <month>Sep</month>
            <day>01</day>
            <volume>177</volume>
            <issue>9</issue>
            <fpage>1308</fpage>
            <page-range>1308-1315</page-range>
            <pub-id pub-id-type="pmid">28604925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17677.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shehab</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Budnitz</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Emergency department visits for antibiotic-associated adverse events.</article-title>
            <source>Clin Infect Dis</source>
            <year>2008</year>
            <month>Sep</month>
            <day>15</day>
            <volume>47</volume>
            <issue>6</issue>
            <fpage>735</fpage>
            <page-range>735-43</page-range>
            <pub-id pub-id-type="pmid">18694344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17677.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gruchalla</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Pirmohamed</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical practice. Antibiotic allergy.</article-title>
            <source>N Engl J Med</source>
            <year>2006</year>
            <month>Feb</month>
            <day>09</day>
            <volume>354</volume>
            <issue>6</issue>
            <fpage>601</fpage>
            <page-range>601-9</page-range>
            <pub-id pub-id-type="pmid">16467547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17677.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Granowitz</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Antibiotic adverse reactions and drug interactions.</article-title>
            <source>Crit Care Clin</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>421</fpage>
            <page-range>421-42, xi</page-range>
            <pub-id pub-id-type="pmid">18361954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17677.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lynch</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Choosing optimal antimicrobial therapies.</article-title>
            <source>Med Clin North Am</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>96</volume>
            <issue>6</issue>
            <fpage>1079</fpage>
            <page-range>1079-94</page-range>
            <pub-id pub-id-type="pmid">23102478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17677.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brauner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fridman</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gefen</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Balaban</surname>
                <given-names>NQ</given-names>
              </name>
            </person-group>
            <article-title>Distinguishing between resistance, tolerance and persistence to antibiotic treatment.</article-title>
            <source>Nat Rev Microbiol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>320</fpage>
            <page-range>320-30</page-range>
            <pub-id pub-id-type="pmid">27080241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17677.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Chopra</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Pathogens resistant to antibacterial agents.</article-title>
            <source>Infect Dis Clin North Am</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>817</fpage>
            <page-range>817-45, vii</page-range>
            <pub-id pub-id-type="pmid">19909886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17677.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Duijkeren</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schink</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Schwarz</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of Bacterial Resistance to Antimicrobial Agents.</article-title>
            <source>Microbiol Spectr</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>6</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">29327680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17677.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leekha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Terrell</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Edson</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>General principles of antimicrobial therapy.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>86</volume>
            <issue>2</issue>
            <fpage>156</fpage>
            <page-range>156-67</page-range>
            <pub-id pub-id-type="pmid">21282489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17677.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fridkin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baggs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fagan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Magill</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pollack</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Malpiedi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Slayton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Khader</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Samore</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dumyati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dodds-Ashley</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Meek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yousey-Hindes</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jernigan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shehab</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Herrera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>A</given-names>
              </name>
              <collab>Centers for Disease Control and Prevention (CDC)</collab>
            </person-group>
            <article-title>Vital signs: improving antibiotic use among hospitalized patients.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2014</year>
            <month>Mar</month>
            <day>07</day>
            <volume>63</volume>
            <issue>9</issue>
            <fpage>194</fpage>
            <page-range>194-200</page-range>
            <pub-id pub-id-type="pmid">24598596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17677.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cunha</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Antimicrobial Stewardship Programs: Principles and Practice.</article-title>
            <source>Med Clin North Am</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>102</volume>
            <issue>5</issue>
            <fpage>797</fpage>
            <page-range>797-803</page-range>
            <pub-id pub-id-type="pmid">30126571</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
